Gilead Sciences, Inc. $GILD Shares Acquired by ABN AMRO Bank N.V.

Key Points

• ABN AMRO Bank N.V. increased its Gilead Sciences stake by 383.5% in the fourth quarter, adding 176,750 shares and bringing its total holdings to 222,841 shares worth about $27.3 million.
• Gilead posted strong first-quarter results, with EPS of $2.03 and revenue of $6.96 billion, both ahead of analyst expectations. The company also raised its Yeztugo 2026 sales guidance to $1 billion from $800 million.
• Despite the upbeat results, Gilead also cut its 2026 EPS outlook to a loss range of -$1.05 to -$0.65 due to acquisition-related charges and financing costs, even as analysts remain broadly constructive with a consensus Moderate Buy rating.

ABN AMRO Bank N.V. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 383.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 222,841 shares of the biopharmaceutical company's stock after acquiring an additional 176,750 shares during the quarter. ABN AMRO Bank N.V.'s holdings in Gilead Sciences were worth $27,281,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Csenge Advisory Group lifted its holdings in shares of Gilead Sciences by 319.0% during the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company's stock worth $2,375,000 after purchasing an additional 16,288 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in shares of Gilead Sciences by 52.1% during the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company's stock worth $8,713,000 after purchasing an additional 26,882 shares during the period. Cookson Peirce & Co. Inc. lifted its holdings in Gilead Sciences by 249.1% in the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company's stock valued at $1,115,000 after acquiring an additional 7,168 shares during the period. Sector Gamma AS lifted its holdings in Gilead Sciences by 15.9% in the third quarter. Sector Gamma AS now owns 147,239 shares of the biopharmaceutical company's stock valued at $16,344,000 after acquiring an additional 20,239 shares during the period. Finally, iA Global Asset Management Inc. boosted its position in shares of Gilead Sciences by 11.6% during the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company's stock worth $24,630,000 after purchasing an additional 23,046 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the transaction, the chief executive officer directly owned 632,567 shares in the company, valued at approximately $81,702,353.72. This trade represents a 1.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total transaction of $463,290.00. Following the transaction, the chief financial officer owned 167,779 shares of the company's stock, valued at $25,910,110.97. This trade represents a 1.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 63,000 shares of company stock worth $9,238,250. 0.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

GILD has been the topic of a number of recent analyst reports. Oppenheimer upped their price target on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 11th. Needham & Company LLC reissued a "buy" rating and set a $170.00 price objective on shares of Gilead Sciences in a report on Monday, February 23rd. TD Cowen upped their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock a "buy" rating in a research report on Wednesday, February 11th. UBS Group increased their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a "buy" rating in a report on Monday, January 26th. Finally, Cantor Fitzgerald reduced their price target on shares of Gilead Sciences from $155.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday, April 10th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $157.15.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Truist Financial reaffirmed its buy rating on Gilead and raised its price target to $157 from $155, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: Gilead reported Q1 EPS of $2.03 and revenue of $6.96 billion, both ahead of analyst expectations, supported by HIV and Trodelvy sales growth. Yahoo Finance
• Positive Sentiment: The company raised its Yeztugo 2026 sales guidance to $1 billion from $800 million, signaling stronger-than-expected launch momentum. Yahoo Finance
• Neutral Sentiment: RBC slightly reduced its price target to $122 from $123 and kept a sector perform view, suggesting a more cautious stance but no major change in thesis. Benzinga
• Negative Sentiment: Gilead cut its 2026 EPS guidance to a loss range of -$1.05 to -$0.65, a major deterioration from prior profit expectations, due to acquisition charges and financing costs. Reuters
• Negative Sentiment: Investors also appear concerned that near-term growth is being driven more by older products like Descovy and Biktarvy than by the much-anticipated Yeztugo launch, creating questions about the pace of future growth. Yahoo Finance

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $131.33 on Monday. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The firm has a 50-day moving average price of $139.59 and a two-hundred day moving average price of $132.87. Gilead Sciences, Inc. has a twelve month low of $96.18 and a twelve month high of $157.29. The company has a market capitalization of $163.06 billion, a P/E ratio of 17.89 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period last year, the firm posted $1.81 EPS. The firm's revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post -0.85 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences's dividend payout ratio (DPR) is 48.45%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.